Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: Neuro-oncology, 2022, art. noac099, S. 1-12
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2022
- Urheber
-
Omuro, Antonio
Brandes, Alba
Carpentier, Antoine
Idbaih, Ahmed
Reardon, David A.
Cloughesy, Timothy
Sumrall, Ashley
Bähring, Joachim
Van den Bent, Martin J.
Bähr, Roy Oliver
Lombardi, Giuseppe
Mulholland, Paul
Tabatabai, Ghazaleh
Lassen, Ulrik
Sepúlveda, Juan Manuel
Khasraw, Mustafa
Vauleon, Elodie
Muragaki, Yoshihiro
Di Giacomo, Anna Maria
Butowski, Nicholas
Roth, Patrick
Qian, Xiaozhong
Fu, Alex Z.
Liu, Yanfang
Potter, Von
Chalamandaris, Alexandros-Georgios
Tatsuoka, Kay
Lim, Michael
Weller, Michael
- DOI
-
10.1093/neuonc/noac099
- URN
-
urn:nbn:de:hebis:30:3-633107
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Omuro, Antonio
- Brandes, Alba
- Carpentier, Antoine
- Idbaih, Ahmed
- Reardon, David A.
- Cloughesy, Timothy
- Sumrall, Ashley
- Bähring, Joachim
- Van den Bent, Martin J.
- Bähr, Roy Oliver
- Lombardi, Giuseppe
- Mulholland, Paul
- Tabatabai, Ghazaleh
- Lassen, Ulrik
- Sepúlveda, Juan Manuel
- Khasraw, Mustafa
- Vauleon, Elodie
- Muragaki, Yoshihiro
- Di Giacomo, Anna Maria
- Butowski, Nicholas
- Roth, Patrick
- Qian, Xiaozhong
- Fu, Alex Z.
- Liu, Yanfang
- Potter, Von
- Chalamandaris, Alexandros-Georgios
- Tatsuoka, Kay
- Lim, Michael
- Weller, Michael
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2022
Ähnliche Objekte (12)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial
MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy
Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
Stanniocalcin-1 promotes temozolomide resistance of glioblastoma through regulation of MGMT
Mitochondria‐Targeted Temozolomide Probe for Overcoming MGMT‐Mediated Resistance in Glioblastoma
Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma
BET protein inhibition sensitizes glioblastoma cells to temozolomide treatment by attenuating MGMT expression
Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma